Kathleen Rodgers completed her Ph.D. in 1984 and joined the faculty at the University of Southern California in 1986 after completing a postdoctoral fellowship. She has focused her career on drug discovery and preclinical development of therapies for the regeneration of damaged tissue. Currently she has developed several products with marketing approval and several others in clinical development including DSC127. She has published over 120 papers in the fields of toxicology, immunology, device development and exploitation of the renin angiotensin system as a platform for drug discovery Kathleen Rodgers completed her Ph.D. in 1984 and joined the faculty at the University of Southern California in 1986 after completing a postdoctoral fellowship. She has focused her career on drug discovery and preclinical development of therapies for the regeneration of damaged tissue. Currently she has developed several products with marketing approval and several others in clinical development including DSC127. She has published over 120 papers in the fields of toxicology, immunology, device development and exploitation of the renin angiotensin system as a platform for drug discovery

toxicology, immunology, device development and exploitation of the renin angiotensin system as a platform for drug discovery